Additionally, it is indicated in combination with G-CSF to enhance mobilization of HSCs to PB for collection and subsequent autologous transplantation in children (aged 1 year to <18 years) with lymphoma or solid malignant tumors, either pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is considered to be insufficient with regards to desired HSCs yield, or in pediatric patients who previously failed to collect sufficient HSCs [18]. This evidence concerns the gene CSF3 and lymphoma.